Financials

News Discussions Technicals Forecast

BIOV fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

BioVersys AG is a clinical stage biopharmaceutical company, which engages in identifying, development, and commercializing novel antibacterial products for infections caused by multi-drug resistant (MDR) bacteria. It is involved in the research and development programs that address nosocomial infections of Acinetobacter baumannii and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

BIOV has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company